Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GTC’s goat milk-derived ATryn approved

Executive Summary

FDA approves the first therapeutic protein derived from a genetically engineered animal Feb. 6. GTC Biotherapeutics' ATryn (recombinant antithrombin III) received approval from both CBER and the Center for Veterinary Medicine to treat patients with the rare clotting disease hereditary antithrombin deficiency. ATryn is the first recombinant antithrombin approved in the U.S. The approval was also a first for CVM - this is the first genetically engineered animal construct to clear FDA, opening the door for future GE animal products in development. Although advisory committee members voted unanimously that a post-marketing study should be conducted to assess the risk/benefit profile after repeat dosing of ATryn, FDA did not mention any required studies in its press release (1"The Pink Sheet," Jan. 19, 2008, p. 27). GTC stated in its announcement that post-marketing studies will be performed to assess safety and immunogenicity after repeat dosing. ATryn should be available by the second quarter, GTC said

You may also be interested in...

For Rare Disorders, Best Shot At Showing Clinical Benefit Is Post-Market –FDA

FDA is acknowledging that clinical benefit for patients with rare conditions may best be verified through post-marketing trials, given the difficulty of conducting clinical trials in those populations

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

Adolescents In COVID-19 Vaccine Trials: As Pfizer Starts Dosing, US FDA Encouraging Other Sponsors

But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts